Cerevel Therapeutics Holdings Inc. (CERE) Is A Stock You Should Watch


As of Wednesday close, Cerevel Therapeutics Holdings Inc.’s (NASDAQ:CERE) stock was up $0.03, moving up 0.10 percent to $29.13. The average number of shares traded per day over the past five days has been 358,840 shares. 3 times new highs have been achieved over the past 5 days, with a $0.70 gain in that time frame. In the last twenty days, the average volume was 542,595, while in the previous 50 days, it was 570,080.

Since last month, CERE stock rose 6.47%. Shares of the company fell to $24.41 on 11/08/22, the lowest level in the past month. A 52-week high of $41.46 was reached on 08/10/22 after having rallying from a 52-week low of $19.86. Since the beginning of this year, CERE’s stock price has dropped by -10.15% or -$3.29, and marked a new high 8 times. However, the stock has declined by -29.74% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


CERE stock investors should be aware that Cerevel Therapeutics Holdings Inc. (CERE) stock had its last reported insider trading activity 23 days ago on Nov 01. Renger John, the Chief Scientific Officer of the company, disposed of 25,000 shares for $30.00 on Nov 01. It resulted in a $750,005 divestment by the insider. Renger John sold 25,000 shares at an average price of $30.00 on Oct 04. The insider now owns 2,704 shares following the transaction. On Sep 12, Director PATRICK DEVAL L sold 47,705 shares at $30.78 apiece. The transaction was valued at $1,468,422.

Financial Health

In the three months ended September 29, Cerevel Therapeutics Holdings Inc.’s quick ratio stood at 16.60, while its current ratio was 16.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.56, and the total debt-to-equity ratio was 0.56.

While analysts expected Cerevel Therapeutics Holdings Inc. to report -$0.62 quarterly earnings, the actual figure was -$0.66 per share, beating the consensus estimate by -6.50%. The liabilities of Cerevel Therapeutics Holdings Inc. were 490.35 million at the end of its most recent quarter ended September 29, and its total debt was $433.11 million. The value of shareholders’ equity is $156.32 million.

Technical Picture

This quick technical analysis looks at Cerevel Therapeutics Holdings Inc.’s (CERE) price momentum. With a historical volatility rate of 51.99%, the RSI 9-day stood at 56.93% on 23 November.

With respect to its five-day moving average, the current Cerevel Therapeutics Holdings Inc. price is up by +2.46% percent or $0.70. At present, CERE shares trade +3.89% above its 20-day simple moving average and -4.90% percent below its 100-day simple moving average. However, the stock is currently trading approximately -1.75% below its SMA50 and +3.41% above its SMA200.

Stochastic coefficient K was 69.39% and Stochastic coefficient D was 65.07%, while ATR was 1.78. Given the Stochastic reading of 79.80% for the 14-day period, the RSI (14) reading has been calculated as 54.96%. As of today, the MACD Oscillator reading stands at -0.28, while the 14-day reading stands at 0.40.

Analyst Ratings

Loop Capital launched its rating on Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) to a Buy in a note to investors on November 01, 2022. Cerevel Therapeutics Holdings Inc. (CERE) has been rated Buy by analysts. According to 0 brokerage firms, CERE is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Cerevel Therapeutics Holdings Inc. stock as buy, with 8 recommending it as overweight.

With a median target price of $40.00, the current consensus forecast for the stock is $28.00 – $52.00. Based on these forecasts, analysts predict Cerevel Therapeutics Holdings Inc. (CERE) will achieve an average price target of $40.44.


Please enter your comment!
Please enter your name here